Due to the emerging links between OXPHOS, neurological disorders (e.g., Alzheimer and Parkinson), and diabetes (Lima et al. 2014; De Felice and Ferreira 2014; Santiago and Potashkin 2014), it is tempting to hypothesize that the identified PARK2 polymorphisms could impact the risk of such human diseases. This evidence concerns the gene PRKN and nervous system disorder.